The effect of methylprednisolone pulse treatment on cytokine network in graves ophthalmopathy

Current Eye Research

Volumn 32, Issue 3, 2007, Pages 291-297

  Lacka, Katarzyna ^a   Manuszewska, Ewa ^a   Korczowska, Izabela ^a   Lacki, Jan K ^b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Cytokines; Glucocorticoid therapy; Graves' ophthalmopathy

Indexed keywords

CYTOKINE; ENZYME ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; METHYLPREDNISOLONE; PEROXIDASE; PREDNISOLONE; THYROGLOBULIN ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG PULSE THERAPY; ENDOCRINE OPHTHALMOPATHY; EUTHYROIDISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-6; METHYLPREDNISOLONE; MIDDLE AGED; PULSE THERAPY, DRUG;

EID: 33947304478     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680601186698     Document Type: Article

References (35)

1. Heufelder AE, Hofbauer LC, Schworm HD. Graves ophthalmopathy- pathogenesis, diagnosis and therapy. Medizinische Welt. 1999;48:230-238.
2. Bahn R. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid associated ophthalmopathy. Thyroid. 2002;12:193-195.
3. Hatton MP, Rubin PA. The pathophysiology of thyroid-associated ophthalmopathy. Ophthalmol Clin North Am. 2002;15:113-119.
4. Kaminski HJ, Li Z, Richmonds C, et al. Susceptibility of ocular tissues to autoimmune diseases. Ann N Y Acad Sci. 2003;998:362-374.
5. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003;24:802-835
6. Smith TJ. Unique properties of orbital connective underlie its involvement in Graves' disease. Minerva Endocrinol. 2003;28:213-222.
7. Weetman AP. Hunt PJ. The immunogenetics of thyroid-associated orbitopathy. Exp Clin Endocrinol Diabetes. 1999;107(Suppl 5):149-151.
8. Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol. 2003; 148:1-9.
9. Salvi M, Pedrazoni M, Girasole G, et al. Serum concentration of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Eur J Endocrinol. 2000;143:197-202.
10. Akira S, Kishimoto T. IL-6 and NF-IL-6 in acute phase response and viral infection. Immunol Rev. 1992;127:25-48.
11. Bahn R. Cytokines in thyroid eye disease: potential for anticytokine therapy. Thyroid. 1998;8:415-418.
12. De Carli M, D'Elios MM, Mariotti S, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab. 1993;77:1120-1124.
13. Guo J, Rapoport B, McLachlan SM. Balance of Th1/Th2 cytokines in thyroid autoantibody synthesis in vitro. Autoimmunity. 1997;30:1-9.
14. Hiromatsu Y, Kaku H, Miyake I, et al. Role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy. Thyroid. 2002;12:217-221.
15. Molnar I, Balazs C. High circulating IL-6 level in Graves' Ophthalmopathy. Autoimmunity. 1997;25:91-96.
16. Mysliwiec J, Kretowski A, Topolska J, et al. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with coticosteroids. Horm Metab Res. 2001;33:738-743.
17. Mysliwiec J, Kretowski A, StepieL A, et al. Interleukin 18 and transforming factor beta 1 in the serum of patients with Graves' ophthalmopathy treated with corticosteroids. Int Immunopharmacol. 2003;3:549-552.
18. Tang L, Luo Q, Zhou X, Xia R. A study of cytokine expression in peripheral blood of patients with Graves' ophthalmopathy. Chung Hua Yen Ko Tsa Chih. 2002;38:165-167.
19. Wakelkamp IM, Prummel MF, Wiersinga WM. Serum IL-18 levels are not increased in patients with untreated Graves' Ophthalmopathy. Horm Metab Res. 2004;26:44-47.
20. Watson PF, Picherill AP, Davies R, Weetman P. Analysis of cytokine gene expression in Graves' disease and multinodular goiter. J Clin Endocrinol Metab. 1994;79:355-360.
21. Grubeck-Loebenstein B, Trieb K, Sztankay A, et al. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest. 1994;3:2738-2743.
22. Jyonouchi SC, Valyasevi RW, Harteneck DA, et al. Interleukin 6 stimulates thyrotropin receptor expression in human orbital preadipocyte fibroblasts from patients with Graves' ophthalmopathy. Thyroid. 2001;11:929-934.
23. Smith TJ. Orbital fibroblasts exbibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. Thyroid. 2002;12:197-2003.
24. Tan GH, Dutton CM, Bahn RS. Interleukin-1 receptor antagonist and soluble IL-1 receptor inhibit IL-1 induced glycosaminoglycans production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metabol. 1996;81:449-452.
25. Walkelkamp IM, Bakker O, Baldeschi L, et al. TSH-r expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol. 2003;58:280-287.
26. Marcocci C, Bartalena L, Marino M, et al. Current medical management of Graves' ophthalmopathy. Ophthal Plast Reconstr Surg. 2002;18:402-408.
27. Terwee CB, Prummel MF, Gerding MN, et al. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol. 2005;62:145-155.
28. Jones TH, Kennedy RL, Justice SK, Davies R. Effect of glucocorticoids and oestrogen on interleukin-6 production by human thyrocyte from patients with Graves' disease and toxic multinodular goitre and from Htori 3 cells. Eur J Endocrinol. 1997;137:429-432.
29. Gorman CA. Clever is not enough: NOSPECS is form in search of function. Thyroid. 1991;1:353-355.
30. Mourits MP, Prummel MF, Wiersinga WM, Koorneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9-14.
31. Werner SC. Modification of the classification of the eye changes of Graves' disease. Recommendation of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 1997;44:203-207
32. Avunduk AM, Avunduk MC, Pazarli H, et al. Immunohistochemical analysis of orbital connective tissue specimens of patients with active Graves ophthalmopathy. Curr Eye Res. 2005;30:631-638.
33. Jones BM, Kwok CC, Kung AW. Effect of radioactive iodine therapy on cytokine production in Graves' disease: transient increases in interleukin 4 (IL-4), IL-6, IL-10 and tumor necrosis factor-alpha with longer term increases in interferon-gamma production. J Clin Endocrinol Metab. 1999;84:4106-4110.
34. Prummel MF, Wiersinga WM. Immunomodulatory treatment of Graves' ophthalmopathy. Thyroid. 1998;8:545-548.
35. Eckstein AK, Plicht M, Lax H, et al. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol (Oxf). 2004;61:612-661.